“It’s a tough three-day ride (not a race),” he wrote.
Here’s the route of the 270-mile ride June 26 through 28:
Day 1: Boston to the University of Connecticut at Storrs (about 105 miles, with killer hill at the end);
Day 2: On to the University of New Haven, with a ferry crossing of the Connecticut River at Hadlyme, and some great riding (about 95 miles); and
Day 3: On to Greenwich, Conn., with the route dipping into New York state for some pretty scenery: fewer miles, but the toughest hills (about 70 miles).
Snodgrass joins the 13th annual Tri-State Trek charity bike ride with the mission to end amyotrophic lateral sclerosis.
ALS, popularized by last summer’s Ice Bucket Challenge, is a progressive neurodegenerative disease that leads to paralysis, and the eventual death of those afflicted. About 30,000 people in the United States now live with ALS, and the average patient survives two to five years following his or her diagnosis.
All proceeds from the ride support the ALS Therapy Development Institute, the world’s first and largest nonprofit biotech focused 100 percent on ALS research.
Snodgrass’s participation in the Trek not only helps raise awareness for ALS, but also the research funds necessary to develop effective treatments, and ultimately a cure.
Donate to Joe’s team >>
Second Arlington rider
In addition, Mark Levine of Arlington is joining those cycling in this effort. He plans to ride 170 miles on the first and last day of the event and was inspired by his experience working with orphan diseases.
“Through my work at Genzyme, I have been acquainted with many people suffering from diseases for which medicine offers little hope,” he said in a news release June 10. “ALS is a terrible representative of this group and participating in fund-raising is the necessary first step in making progress.”
To support Levine’s efforts, click here >>
For more information on riding, volunteering, or com
In the past 12 years, riders and volunteers of the Tri-State Trek have raised more than $6 million for the ALS Therapy Development Institute. With this support, the institute has been able to move projects and partnerships forward toward the goal of ending ALS through research initiatives such as the completion of its Phase IIA clinical trial of Gilenya in ALS, the expansion of its Precision Medicine Program, and the acceleration (of the clinical development) of two potential treatments for ALS.
For more information about riding, volunteering or coming out to cheer, call 617-441-7200 or visit www.TriStateTrek.com.
This story was published Sunday, May 17, 2017, and updated June 10, to add an Arlington rider.
